Search results
Results from the WOW.Com Content Network
Evolocumab, [6] sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia. Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) .
Repatha is a brand name for the injectable drug evolocumab. Repatha treats high cholesterol and reduces the risk of heart attack , stroke, and certain types of heart surgery in adults with ...
Causes: Idiopathic, Kawasaki disease, Parkinson's disease, Chagas disease, Hirschsprung's disease, intestinal hypogangliosis, collagen vascular disease, mitochondrial disease, endocrine disorders, medication side effects: Diagnostic method: Signs and symptoms consistent with a mechanical intestinal obstruction with no identifying lesion.
Bowel infarction or gangrenous bowel represents an irreversible injury to the intestine resulting from insufficient blood flow. It is considered a medical emergency because it can quickly result in life-threatening infection and death. [1] Any cause of bowel ischemia, the earlier reversible form of injury, may ultimately lead to infarction if ...
Irritable bowel disease (IBD), which includes ulcerative colitis or Crohn’s disease, causes inflammation in the digestive tract, leading to a range of symptoms including pain, diarrhea, and less ...
Functional abdominal pain syndrome is a functional gastrointestinal disorder. [4] Functional gastrointestinal disorders (FGD) are common medical conditions characterized by recurrent and persistent gastrointestinal symptoms caused by improper functioning of the enteric system in the absence of any identifiable organic or structural pathology, such as ulcers, inflammation, tumors or masses.
Neurogenic bowel dysfunction (NBD) is reduced ability or inability to control defecation due to deterioration of or injury to the nervous system, resulting in fecal incontinence or constipation. [1] It is common in people with spinal cord injury (SCI), multiple sclerosis (MS) or spina bifida .
However, instances with symptoms and signs of a bowel obstruction occur, but with the absence of a mechanical obstruction, mainly in acute colonic pseudo-obstruction, Ogilvie's syndrome. [3] In 2023 the US FDA reported gastrointestinal ileus as an adverse effect of the medication semaglutide , with frequency and causal relationship unknown.